The laboratory is working on understanding the molecular mechanisms by which acute lymphoblastic leukemia cells survive extensive chemotherapy. We are engaged in several projects using a combination of genetic, bioinformatics and biochemical tools to analyze the functions of specific target proteins and their role in the pathogenesis of acute lymphoblastic leukemia. The goal of our research is to uncover the underlying mechanisms of therapy resistance and to develop less toxic, highly effective molecularly-targeted therapies against acute lymphoblastic leukemia. The lab is mainly focusing on childhood leukemia as this group of patients suffers from long-term side effect of the current therapies.

Read more about us @ Lund UniversityTranslational Cancer Research



Hyrenius-Wittsten A., Pilheden M., Sturesson H., Hansson J., Walsh M. P., Song G., Kazi J.U., Liu J., Ramakrishan R., Garcia-Ruiz C., Nance S., Gupta P., Zhang J., Rönnstrand L., Hultquist A., Downing J. R., Lindkvist-Petersson K., Paulsson K., Järås M., Gruber T. A., Ma J., and Andersson-Hagström A. K. (2018) De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nature Communications 9(1): 1770 (Pubmed,  Link, Lund University, ResearchGate).

Rupar K., Moharram S.A., Kazi J.U. and Rönnstrand L (2018) Src-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation. Scientific Reports 8(1): 6405 (PubmedLinkLund UniversityResearchGate).

Moharram S.A., Shah K. and Kazi J.U. (2017) T-cell acute lymphoblastic leukemia cells display activation of different survival pathways. Journal of Cancer 8(19): 4124-4129 (PubmedLinkLund UniversityResearchGate).

Moharram S.A., Shah K., Khanum F., Marhäll A., Gazi M. and Kazi J.U. (2017) Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia. Cancer Letters 405(1): 73-78 (PubmedLinkLund UniversityResearchGate).

Gazi M., Moharram S.A., Marhäll A. and Kazi J.U. (2017) The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Cancer Letters 392(1): 9-16 (Pubmed, LinkLund University, ResearchGate).



Rönnstrand Lab
Acrivon AB